Perimyocarditis has occurred in adolescent males 1–3 days following inoculation with the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech), but all cases are mild, reports an Israel study, noting that only long-term follow-up can reveal the true impact of this transient cardiac injury.
Lung ultrasound proves to be a useful tool for screening community-acquired pneumonia in the emergency department (ED), with a recent study showing that its use brings down diagnostic uncertainty from 73 percent to 14 percent.
Systemic manifestations of SARS-CoV-2 infection vary but are interconnected by shared mechanisms, according to a Singapore study, which has identified two phases of extrapulmonary disease. The first one is an early phase with possible gastrointestinal, ocular, and cutaneous involvement and, second, a late phase characterized by multiorgan dysfunction and clinical deterioration.
Treatment with a combination of the recombinant human IgG1 monoclonal antibodies casirivimab and imdevimab reduced hospitalization rates in high-risk patients with mild-to-moderate COVID-19, according to results of a retrospective study.
There is significant increase in SARS-CoV-2-specific antibodies in breast milk of mothers following vaccination against COVID-19 — indicating its potential in conferring protection against the illness to breastfeeding infants, according to a study.
air samplers are able to detect airborne SARS-CoV-2 in hospitals, outperforming
even surface sampling, according to a recent Singapore study. Factors such as
the site of deployment and distance of the air samplers from patients affect
the viral load detected.
A new antibiotic-beta lactamase combination has been approved for the treatment of complicated intra-abdominal infection (cIAI) in combination with metronidazole, complicated urinary tract infection (cUTI) including pyelonephritis, and hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP).
Investigations into the role of small aerosol particles in COVID-19 transmission suggest that SARS-CoV-2 may be an airborne hazard. A recent medRxiv preprint study from Singapore adds to this body of evidence.